Peregrine Pharmaceuticals Highlights Promising Early Data From Its Three Phase II Bavituximab Cancer Trials

- 71% Objective Tumor Response in Combination with Docetaxel in Advanced Breast Cancer - - 65% Objective Tumor Response in Combination with Carboplatin/Paclitaxel in Advanced Lung Cancer - - 64% Objective Tumor Response in Combination with Carboplatin/Paclitaxel in Advanced Breast Cance...

AlphaVax Announces Promising Results in Melanoma Studies

RESEARCH TRIANGLE PARK, N.C., May 13 /PRNewswire/ -- AlphaVax announced today the presentation of promising results from a collaboration with researchers at the Memorial Sloan-Kettering Cancer Center (MSKCC). Francesca Avogadri, Ph.D., a Research Fellow in the Department of Medicine at MSKCC prese...

Results From Study Show Promising Efficacy and Safety Results for Corthera's Relaxin in Acute Heart Failure

Data Presented at Late-Breaking Clinical Trials Session at ACC 58th Annual Scientific Session; Results Published On-Line in The Lancet SAN MATEO¿ Calif.¿ March 29 /PRNewswire/ -- Corthera Inc. today announced that results from Pre-RELAX-AHF, the Phase II portion of a Phase II/III multicenter,...

Genaera Presents Promising Preclinical Data for Trodusquemine (MSI-1436) at Keystone Symposia

- Subcutaneous Administration of MSI-1436 in DIO Rats Highlighted - PLYMOUTH MEETING, Pa., Jan. 22 /PRNewswire-FirstCall/ -- Genaera Corporation (Nasdaq: GENR ) today announced a poster presentation of preclinical data on trodusquemine (MSI-1436), Genaera's lead drug candidate for the tre...

Chipscreen Biosciences and HUYA Bioscience Int'l Announce Promising Preclincial and Phase I Solid Tumor/Lymphoma Data for Chidamide/HBI-8000, New HDAC Inhibitor for Cancer

First Compound Sourced from China Shows Strong Results Presented at Cambridge Healthtech Institute Fall Conference BOSTON, Oct. 23 /PRNewswire/ -- CHI -- Chipscreen Biosciences (Chipscreen) and HUYA Bioscience International (HUYA) today described the preclinical profile and outco...

Surveyed Oncologists Say That the Most Promising Targeted Therapy in Adjuvant Clinical Trials is Avastin for the Treatment of Early-Stage Colorectal Cancer

Despite Widespread Use, Formulary Coverage of Targeted Cancer Therapies is Inconsistent, According to a New Report from Decision Resources WALTHAM, Mass., Oct. 14 /PRNewswire/ -- Decision Resources, one of the world's leading research and advisory firms for pharmaceutical and healthcare issu...

NVA237 Phase II Results Presented at the European Respiratory Society Annual Meeting Show Promising Efficacy and Tolerability With Potentially Faster Onset Than Tiotropium

TOKYO and CHIPPENHAM, England, October 7 /PRNewswire-FirstCall/ -- Sosei Group Corporation ("Sosei"; TSE Mothers Index: 4565) and Vectura Group plc ("Vectura"; LSE: VEC), announce results of two Phase II studies evaluating the efficacy, safety and tolerability of NVA237 presented at the annual...

Amylin Pharmaceuticals to Present Novel Data on Promising Obesity Pipeline at 2008 Annual Scientific Meeting of The Obesity Society

Data support the therapeutic potential of Amylin's integrated neurohormonal approach to obesity pharmacotherapy SAN DIEGO, Oct. 1 /PRNewswire-FirstCall/ -- Amylin Pharmaceuticals, Inc. (Nasdaq: AMLN ) today announced that new data for its pipeline obesity candidates will be pre...

ThromboGenics Announces Promising Results of MITI IV Phase II Trial in the Treatment of Acute Stroke with Microplasmin

LEUVEN, Belgium, September 29 /PRNewswire-FirstCall/ -- - Results Presented at World Stroke Congress in Vienna ThromboGenics NV (Euronext Brussels: THR), a biotechnology company focused on novel therapies for eye disease, vascular disease and cancer, announces positive results from its MIT...

Bioheart Reports Promising Results From Preclinical Study of Adipose-Derived Acute Cell Therapy

SUNRISE, Fla., Sept. 18 /PRNewswire/ -- A preclinical study involving the injection of adipose-derived stem cells (ADSCs) into the myocardium (heart muscle tissue) of infarcted rats, was recently completed at the Jordan University of Science and Technology in Irbid, Jordan by medical and veteri...

Symposium Highlights Yale Study Indicating Role of AHCC(R) for Immune System Enhancement and as a Promising Cancer Preventative

Significant Research Presented at the AHCC International Research Symposium PURCHASE, N.Y., Sept. 16 /PRNewswire/ -- The 16th International AHCC(R) (Active Hexose Correlated Compound) Symposium was held in Sapporo, Japan on July 26th and 27th. The Symposium hosted by the AHCC Research Associatio...

Bioheart Reports Promising Results From SDF-1 Modified MyoCell(R) Therapy in Heart Failure Study

Pre-Clinical Data Shows Increased Muscle and Blood Vessel Formation in Animals' Hearts SUNRISE, Fla., July 24 /PRNewswire-FirstCall/ -- Results of a preclinical study involving the injection of myoblasts modified to express stromal derived factor-1(alpha) protein (S...

Michael J. Fox Foundation Awards $2.4 Million for Validation of Nine Promising Therapeutic Targets for Parkinson's Disease

NEW YORK, July 17 /PRNewswire-USNewswire/ -- The Michael J. Fox Foundation for Parkinson's Research today announced approximately $2.4 million in total funding to nine research teams under its Target Validation initiative. This annual MJFF program provides intellectual and financial resources ...

HUYA Bioscience Int'l Announces Pre-IND Outcome for HBI-3000 - Promising Anti-Arrhythmia Compound Sourced From China

FDA Feedback Supports Innovative Co-development Model SAN DIEGO, June 17 /PRNewswire/ -- Bio International Convention 2008 ( http://www.bio2008.org ) -- HUYA Bioscience International ( http://www.huyabio.com ), the leader in U.S./China pharmaceutical co-development, today announced th...

Genaera Corporation Presents Additional Promising Preclinical Type 2 Diabetes Data for Trodusquemine (MSI-1436) at American Diabetes Association

PLYMOUTH MEETING, Pa., June 9 /PRNewswire-FirstCall/ -- Genaera Corporation (Nasdaq: GENR ) announced today a presentation by Genaera scientists of preclinical data on trodusquemine (MSI-1436), Genaera's lead drug candidate for the treatment of type 2 diabetes and obesity, during the 68th Sci...

Jennerex Publishes Promising Results from Cancer Clinical Trial of JX-594 in Lancet Oncology

Tumor responses, safety and long-term survivors validate Jennerex breakthrough product approach SAN FRANCISCO and YONGIN-SI, South Korea, May 21 /PRNewswire/ -- Jennerex, Inc. (San Francisco, CA and Ottawa, Ontario), and its South Korean partner Green Cross Corp., announ...

Amikacin Inhale Shows Promising Results in Phase II Study

- Bayer together with Nektar Therapeutics present preliminary Phase II data for the adjunctive treatment of pneumonia in intubated and mechanically-ventilated patients TORONTO and BERLIN, May 19 /PRNewswire-FirstCall/ -- Bayer HealthCare together with Nektar Therapeutics...

HUYA Bioscience Int'l Announces First Pre-IND Outcome for a Development Stage Compound Sourced From China - HBI-8000, Promising New Cancer Compound

FDA feedback validates HUYA's Integrated Co-Development Model for China-sourced Drug Candidates SAN DIEGO, April 14 /PRNewswire/ -- HUYA Bioscience International (HUYA), the leader in U.S./China pharmaceutical co-development, today announced the outcome of the first pre-...

HUYA Bioscience Int'l Announces Clinical Trial Milestones in China for Promising New Anti-Arrhythmic Compound; Data Supports Desirable Safety Profile

Progress validates HUYA's innovative U.S./China pharmaceutical co-development model SAN FRANCISCO, March 3 /PRNewswire/ -- IBC Conference -- HUYA Bioscience International (HUYA), the leader in U.S./China pharmaceutical co-development, today announced the completio...

Michael J. Fox Foundation Awards Up to $3 Million to Industry Teams to Jumpstart Promising PD Drug Development

Four industry research projects targeted as part of innovative Therapeutics Development Initiative NEW YORK, Jan. 31 /PRNewswire-USNewswire/ -- As part of its ongoing efforts to do whatever it takes to speed delivery of transformative treatments and a cure for Parkinson's disease, The Mich...

Genaera Corporation Presents Promising Preclinical Type 2 Diabetes Data for Trodusquemine (MSI-1436) at Keystone Symposia

New data supports recent IND and forms foundation for upcoming clinical programs PLYMOUTH MEETING, Pa., Jan. 24 /PRNewswire-FirstCall/ -- Genaera Corporation (Nasdaq: GENR ) announced today a poster presentation of preclinical data on trodusquemine (MSI-1436), G...

Protalix BioTherapeutics Extends Research Agreement With Yissum Based on Promising Acetylcholinesterase Program Results in Animal Study

CARMIEL, Israel, Jan. 22 /PRNewswire-FirstCall/ -- Protalix BioTherapeutics, Inc. (Amex: PLX ), today announced that it has achieved proof of concept results in an animal study conducted as part of its Acetylcholinesterase (AChE) Program. The Acetylcholinesterase (AChE) Program is being condu...

AmpliMed Corporation Announces Promising 1-year Survival Data from Phase I/II Study of Amplimexon(R) in Metastatic Malignant Melanoma

TUCSON, Ariz., Jan. 3 /PRNewswire/ -- AmpliMed today reported one year survival results from a Phase I/II trial of its lead drug candidate, Amplimexon(R) (imexon for injection) in combination with dacarbazine in patients with unresectable stage III or stage IV metastatic malignant melanoma. Re...

Cutanea Announces Promising Phase II Results in Rosacea with Omiganan

Plans to Move Forward with Phase III MALVERN, Pa., Oct. 17 /PRNewswire/ -- Cutanea Life Sciences, an emerging specialty pharmaceutical company focused on improving human health and appearance through the development and commercialization of treatments for diseased and aging s...

NicOx and Ferrer Present Promising Clinical and Preclinical Results in Dermatology

SOPHIA ANTIPOLIS, France, Oct. 2 /PRNewswire-FirstCall/ -- NicOx S.A. (Eurolist: COX) today announced the presentation of promising clinical and preclinical results from its collaboration with Ferrer Grupo International at the 21st World Congress of Dermatology, in Buenos Aires, Argentina. The...

The Leukemia & Lymphoma Society is Encouraged by Promising News for Myeloma Patients

WHITE PLAINS, N.Y., Sept. 18 /PRNewswire/ -- Millennium Pharmaceuticals and Johnson & Johnson have reported that an interim analysis of a large, randomized, international Phase III trial comparing melphalan-prednisone (MP) with MP in combination with Velcade(R) (bortezomib) showed that the pat...

NicOx Reports TOPIGEN to Advance TPI-1020 Into Phase 2 for COPD Following Promising Clinical Results

SOPHIA ANTIPOLIS, France, Sept. 11 /PRNewswire/ -- NicOx S.A. (Eurolist: COX) today reported that TOPIGEN Pharmaceuticals Inc. has disclosed promising top-line results from its first phase 2 clinical study for TPI-1020, a new chemical entity licensed from NicOx which is a novel respiratory ant...

Kiadis Pharma Announces Promising Phase II Clinical Trial Results for Reviroc

GRONINGEN, Netherlands, Aug. 31 /PRNewswire-FirstCall/ -- Oncology focused pharmaceutical development company Kiadis Pharma announced today that it has successfully completed a Phase II clinical trial evaluating its product Reviroc(TM). Reviroc is used to eliminate cancer cells from an autolog...

ImmuneRegen BioSciences Announces Promising Data on Homspera Suggesting Potential as a Co-Therapeutic Agent

Compound Could Be Utilized as an Adjuvant and Play Key Role in the Treatment of Influenza and Cancer SCOTTSDALE, Ariz., March 20, 2007 /PRNewswire-FirstCall/ -- ImmuneRegen BioSciences, a wholly owned subsidiary of IR BioSciences Holdings, Inc. , announced today that data obtained by the Company o...

Arpida Announces Promising Results of "First-In-Man" Studies With AR-709

High Concentrations Reached in Key Lung Compartments REINACH and BASEL, Switzerland, March 29, 2007 /PRNewswire-FirstCall/ -- Arpida Ltd. today announced promising results of "first-in-man" studies with AR-709. These radiolabelled Human Microdose studies included a total of 19 healthy male volunte...

PharmAthene's Recombinant Butyrylcholinesterase (rBChE) Program the Subject of Promising New Alzheimer's Research

In Vitro Assays Show rBChE Suppresses Amyloid Plaque Formation ANNAPOLIS, Md., April 03, 2007 /PRNewswire/ -- PharmAthene, Inc., a leading biodefense company specializing in the development and commercialization of medical countermeasures against chemical and biological terrorism, announced today ...

Pharmathene's Recombinant Butyrylcholinesterase (rBChE) Program the Subject of Promising New Alzheimer's Research

In Vitro Assays Show rBChE Suppresses Amyloid Plaque Formation ANNAPOLIS, Md., April 3, 2007 - PharmAthene, Inc., a leading biodefense company specializing in the development and commercialization of medical countermeasures against chemical and biological terrorism, announced today that new data...

Biomira Selects PX-866 as Clinical Development Candidate and Presents Promising Preclinical Data at AACR

-IND filing expected by end of 2007- EDMONTON, April 16, 2007 /PRNewswire-FirstCall/ - Biomira Inc. today announced that it has selected PX-866 as its next clinical development candidate. PX-866 is an inhibitor of the phosphatidylinositol-3-kinase (PI3 kinase)/ PTEN/AKT pathway, an important survi...

Targeting Specific Mutations Reveals Promising New Approach to Treating Genetic Disorders; Preclinical Data Published in Nature

PTC124 Targets Nonsense Mutations; Addresses Underlying Cause of Genetic Disorders and Restores Protein Function SOUTH PLAINFIELD, N.J., April 23, 2007 /PRNewswire/ -- New preclinical data published online in the current edition of the journal Nature show that PTC124, an investigational new drug d...

Insmed Announces Promising Results From IPLEX Phase II Myotonic Muscular Dystrophy Clinical Study

RICHMOND, Va.--(BUSINESS WIRE)--May 3, 2007 - Insmed Inc. (Nasdaq:INSM) today announced positive results from a Phase II investigator-sponsored study of the company's drug, IPLEX(TM), in patients with myotonic muscular dystrophy (DM1). Preliminary results of the clinical study, being conducted at ...

Samaritan Announces Positive Data in Nonclinical (IND) In-Vitro Studies for Promising Alzheimer's Drug

Samaritan Announces Positive Data in Nonclinical (IND) In- Vitro Studies for Promising Alzheimer's Drug LAS VEGAS, May 3, 2007 (PRIME NEWSWIRE) -- Samaritan Pharmaceuticals Inc. (AMEX:LIV), a developer of innovative drugs, is pleased to announce positive results were attained with its late-stage p...

IR BioSciences Announces Promising Data from Study of Its Compound Homspera

Data Suggests Homspera Shows Promise As an Adjuvant for Vaccines against Avian Flu and Other Viruses SCOTTSDALE, Ariz., May 07, 2007 /PRNewswire-FirstCall/ -- IR BioSciences Holdings, Inc. announced today that preliminary data from its influenza vaccine adjuvant study being performed in conjunctio...

XTENT Announces Promising Six-Month Custom II Trial Data Presented at EuroPCR Meeting

Trial Included One of the Most Challenging Patient Populations Studied of Any Drug-Eluting Stent (DES) Clinical Trial BARCELONA and MENLO PARK, Calif., May 22, 2007 /PRNewswire-FirstCall/ -- XTENT, Inc. announces positive six-month follow-up data from the CUSTOM II clinical trial, which assessed t...

Introgen Reports Promising Phase 1/2 Clinical Results With INGN 241 in Patients With Advanced Solid Tumors

SEATTLE--(BUSINESS WIRE)--Jun 1, 2007 - Introgen Therapeutics, Inc. (NASDAQ:INGN) reported promising Phase 1/2 clinical data with INGN 241, the Company's novel investigational mda-7/IL-24 tumor suppressor agent, in patients with advanced solid tumors. The data (Abstract #380), which were presented...

Poniard Pharmaceuticals Announces Promising Data From Interim Safety Analysis of Phase 1 Combination Trials of Picoplatin in Colorectal and Prostate Cancers

- Company Planning to Initiate Phase 2 Trials in Colorectal Cancer and in Hormone-Refractory Prostate Cancer in Q307 - SOUTH SAN FRANCISCO, Calif., June 01, 2007 /PRNewswire-FirstCall/ -- Poniard Pharmaceuticals, Inc. , a biopharmaceutical company focused on oncology, today announced promising res...